Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

MJ-355: a new K(ATP) channel opener with antihypertensive and cardioprotective effects

Dec. 22, 1999

Pretreatment with complement inhibitor significantly reduces cardiac, brain damage following CPB

Dec. 22, 1999

Bristol-Myers Squibb seeks regulatory approvals worldwide for Vanlev

Dec. 21, 1999

New cardiovascular agents from Yamanouchi

Dec. 21, 1999

German launch and local distributor announced for Tanabe's ACE inhibitor

Dec. 21, 1999

CV Therapeutics receives SBIR grant to study effects of adenosine in angiogenesis

Dec. 21, 1999

AVI BioPharma's restenosis antisense compound enters phase I trials

Dec. 17, 1999

Novel inotropic agent EGIS-9377: potential advantages in the treatment of CHF

Dec. 16, 1999

Indian scientists explore mechanism of cardioprotective effect of PAF antagonist

Dec. 15, 1999

Concor COR cleared for marketing in Germany as heart failure treatment

Dec. 15, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...